[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647384":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":20,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":20,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Fondazione Don Carlo Gnocchi ETS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Biomarker Assessment","EXPERIMENTAL","Participants with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or resectable lung carcinoma will undergo peripheral blood collection at baseline for inflammatory, immunological, genetic, and epigenetic biomarker analyses. Clinical and functional data will be collected at baseline, and participants will undergo a 12-month follow-up to evaluate the prognostic value of the identified biomarkers.",[13],"Procedure: Peripheral Blood Collection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Peripheral Blood Collection","Peripheral venous blood collection (approximately 40 mL) for inflammatory, immunological, genetic, and epigenetic biomarker analyses, including PBMC isolation, serum collection, genomic DNA extraction, and microRNA analysis.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Mario Clerici, MD","IRCCS Fondazione Don Carlo Gnocchi","PRINCIPAL_INVESTIGATOR",[27,31],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","+39024030801","mario.clerici@unimi.it",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Simone Agostini, PhD","+390240308375","sagostini@dongnocchi.it",[36],{"facility":24,"status":37,"city":38,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Milan","20148","Italy","IT",{"type":43,"coordinates":44},"Point",[45,46],9.18951,45.46427,{"lat":46,"lon":45},[49,50],{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":53},"Federica Piancone, PhD","+390240308211","fpiancone@dongnocchi.it",{"type":55,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[57],{"name":58,"class":59},"Trust Franco e Piero Gazzarrini","UNKNOWN","100647384","identification-of-diagnostic-and-prognostic-biomarkers-in-the-pathological-continuum-of-bronco-chronic-obstructive-pulmonary-disease-idiopathic-pulmonary-fibrosis-and-pulmonary-neoplasia-100647384",false,"NCT07707245","Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia","RESPIRO","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of: Chronic Obstructive Pulmonary Disease (COPD), current or former smokers; and\u002For Idiopathic Pulmonary Fibrosis (IPF), current or former smokers; and\u002For Resectable lung adenocarcinoma (Stage I-III, according to clinical indication for surgical resection).\n* Ability to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent.\n* Active respiratory infection or acute exacerbation of COPD or IPF at the time of enrollment.\n* Previous or concomitant malignant disease (except non-melanoma skin cancer) that could interfere with study objectives.\n* Prior systemic immunosuppressive or anti-inflammatory therapy that may significantly alter immune profiling within a defined washout period (if applicable per protocol).\n* Severe comorbid conditions limiting life expectancy or ability to complete follow-up (e.g., advanced heart failure, severe renal or hepatic disease).\n\nInadequate biological sample quality or impossibility to obtain required blood samples.","ALL","18 Years",{"count":70,"type":71},120,"ESTIMATED","INTERVENTIONAL",[74],"NA","Primary Objective:\n\nTo evaluate the association between inflammatory, immunological, genetic, and epigenetic biomarkers measured at enrollment and the clinical, functional, and phenotypic characteristics of patients with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer.\n\nSecondary Objective:\n\nTo assess the prognostic value of the identified biomarkers by evaluating their ability to predict clinical outcomes at 12 months.\n\nPrimary Outcome Measure:\n\nAssociation between baseline inflammatory, immunological, genetic, and epigenetic biomarkers and disease-specific clinical, functional, and phenotypic characteristics assessed at enrollment, including:\n\nCOPD: current or former smokers, stratified according to the predominant phenotype (emphysema or bronchiolitis); IPF: rapid progressors, slow progressors, and patients with combined pulmonary fibrosis and emphysema (CPFE); Lung cancer: current smokers, former smokers who quit less than 15 years before enrollment, former smokers who quit 15 years or more before enrollment, and never-smokers.\n\nSecondary Outcome Measure:\n\nPredictive performance of baseline inflammatory, immunological, genetic, and epigenetic biomarkers for 12-month clinical outcomes.",[77,78,79],"COPD","Idiopathic Pulmonary Fibrosis (IPF)","Lung Cancer","2026-07-15",{"date":82,"type":83},"2026-07-16","ACTUAL",{"date":85,"type":83},"2026-04-22",{"date":87,"type":71},"2028-10-30",{"name":5,"class":6},1]